World's Best Scientists 2026 revealed!
Sumanta K. Pal

Sumanta K. Pal

D-Index & Metrics

Medicine

D-Index
95
Citations
36591
World Ranking
9993
National Ranking
5143

Sumanta K. Pal publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sumanta K. Pal sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,247 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sumanta K. Pal D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sumanta K. Pal sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sumanta K. Pal is a researcher affiliated with City of Hope in the United States, with a primary focus on medicine and related biomedical fields. Their work spans several areas within oncology and molecular biology, building a significant portfolio of publications and collaborations.

The main fields of study associated with Sumanta K. Pal include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research delves into multiple subfields, such as:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Surgery
  • Molecular Biology
  • Cancer Research

Sumanta K. Pal's work addresses key topics including:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Renal and related cancers
  • Economic and Financial Impacts of Cancer
  • Urinary and Genital Oncology Studies

Their recent papers illustrate active engagement with clinical oncology and cancer treatment research. Selected publications include:

  • "Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology" (2020), published in Journal of the National Comprehensive Cancer Network
  • "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial" (2020), published in Nature Medicine
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma" (2020), published in Annals of Oncology
  • "Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial" (2022), published in Nature Medicine
  • "A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial" (2021), published in The Lancet

Frequent co-authors collaborating with Sumanta K. Pal include:

  • Nazlı Dizman
  • Toni K. Choueiri
  • Luís Meza
  • Alex Chehrazi-Raffle
  • Tanya B. Dorff

The most common venues where Sumanta K. Pal publishes work are:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • European Urology

Best Publications

  • Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Padmanee Sharma;Margitta M. Retz;Arlene Siefker-Radtke;Ari D. Baron

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.

    Saro H. Armenian;Lanfang Xu;Bonnie Ky;Canlan Sun

  • Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Hans J. Hammers;Elizabeth R. Plimack;Jeffrey R. Infante;Brian I. Rini

  • Bladder cancer. Clinical practice guidelines in oncology.

    Peter E. Clark;Neeraj Agarwal;Matthew C. Biagioli;Mario A. Eisenberger

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Triple negative breast cancer: unmet medical needs.

    Sumanta Kumar Pal;Barrett H. Childs;Mark Pegram

  • Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

    Robert J. Motzer;Paul B. Robbins;Thomas Powles;Laurence Albiges

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Bladder cancer, version 5.2017: Clinical practice guidelines in oncology

    Philippe E. Spiess;Neeraj Agarwal;Rick Bangs;Stephen A. Boorjian

  • Evaluating the older patient with cancer: understanding frailty and the geriatric assessment.

    Sumanta Kumar Pal;Vani Katheria;Arti Hurria

  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

    Asim Amin;Elizabeth R. Plimack;Jeffrey R. Infante;Marc S. Ernstoff

  • Impact of age, sex, and comorbidity on cancer therapy and disease progression.

    Sumanta Kumar Pal;Arti Hurria

  • Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

    Nils Kroeger;Wanling Xie;Jae Lyn Lee;Georg A. Bjarnason

  • Akt inhibitors in clinical development for the treatment of cancer

    Sumanta Kumar Pal;Karen Reckamp;Hua Yu;Robert A Figlin

  • S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

    Jiehui Deng;Yong Liu;Heehyoung Lee;Andreas Herrmann

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study

    Nawar Hanna;Maxine Sun;Christian P. Meyer;Paul L. Nguyen

Frequent Co-Authors

Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Hua Yu
Hua Yu City Of Hope National Medical Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Thomas Powles
Thomas Powles Queen Mary University of London
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have more opportunities than ever to advance their careers through online education. For those looking outside the traditional MD route, related health degrees and certifications can open doors to in-demand roles in healthcare.

Pharmacists remain essential to patient care. Those interested can now access online pharmacy schools offering affordable Doctorate in Pharmacy programs, ideal for busy students or working adults. Similarly, the demand for Nurse Practitioners continues to rise. If you’re considering this path, there are affordable online fnp programs that let you balance study with life responsibilities.

Medical billing and coding are vital to quality healthcare administration. Anyone looking to start a career in this field can find respected medical billing and coding certification online programs. If you are still in high school or just starting to explore healthcare pathways, check out the best online schools for high school students with strong health information management tracks.

With these flexible online options, a rewarding healthcare career could be within reach—no matter your educational background or current stage in life.

Best Scientists Citing Sumanta K. Pal

Trending Scientists

Recently Published Articles